Pursuant to Regulation 30 (6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, Wanbury (WL) has informed the following: 1. Sertraline Form II approval received from ANVISA, BRAZIL. This is in addition to Sertraline hydrochloride Form 1 approval that Wanbury already has. WL currently hold 75% market share for sertraline in Brazil's market. Approval for Form II, will help in further consolidation company's share of business. 2. WL has received approval from one of the largest customers for a special grade of metformin. DC grade with potential business opportunity to be estimated around Rupees 15 crore per annum. Both the API manufacturing sites i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: